07:34 AM EDT, 07/17/2025 (MT Newswires) -- Harrow Therapeutics (HROW) said Thursday it has secured exclusive US commercial rights from Samsung Bioepis for two ophthalmology biosimilars targeting retinal diseases.

The portfolio of drugs to treat retinal disease includes Byooviz, a biosimilar of Lucentis, and Opuviz, a biosimilar of Eylea.

Upon completion of this transition, expected by the end of 2025, Harrow will assume full U.S. commercialization responsibilities for Byooviz, the company said.